Semen astragali complanati- and rhizoma cibotii-enhanced bone formation in osteoporosis rats
© Liu et al.; licensee BioMed Central Ltd. 2013
Received: 13 January 2012
Accepted: 13 June 2013
Published: 20 June 2013
Growing evidence shows that herb medicines have some anti-osteoporotic effects, the mechanism underlying is unknown. This study aims to investigate the therapeutic effect of Chinese herb supplements on rats that had osteoporosis-like symptom induced by ovariectomy (OVX).
OVX or sham operations were performed on virgin Wistar rats at three-month old, which were randomly divided into eight groups: sham (sham); OVX control group (OVX); OVX rats with treatments [either diethylstilbestrol (DES) or Semen Astragali Complanati decoction (SACD) or Rhizoma Cibotii decoction (RCD) or Herba Cistanches decoction (HCD) or Semen Allii Tuberosi decoction (SATD)]. Non-surgical rats were served as a normal control (NC). The treatments began 4 weeks after surgery, and lasted for 12 weeks. Bone mass and its turnover were analyzed by histomorphometry. Levels of protein and mRNA of osteoprotegerin (OPG) and receptor activator of nuclear factor κ B ligand (RANKL) in osteoblasts (OB) and bone marrow stromal cells (bMSC) were evaluated by immunohistochemistry and in situ hybridization.
Compared to OVX control, TBV% in both SACD and RCD groups was increased significantly, while TRS%, TFS%, MAR, and mAR were decreased remarkably in the SACD group, only TRS% decreased dramatically in the RCD group. No significant changes in bone formation were observed in either HCD or SATD groups. OPG levels in both protein and mRNA were reduced consistantly in OB and bMSC from OVX control rats, in contrast, RANKL levels in both protein and mRNA were increased significantly. These effects were substantially reversed by treatments with either DES or SACD or RCD. No significant changes in both OPG and RANKL expression were observed in OB and bMSC from OVX rats treated with SATD and HCD.
Our study showed that SACD and RCD increased bone formation by stimulating OPG expression and downregulating RANKL expression in OB and bMSC. This suggests that SACD and RCD may be developed as alternative anti-osteoporotic agents for therapy of postmenopausal osteoporosis.
Osteoporosis often occurs in postmenopausal women, and older men. Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an increased risk fragility fractures . Bone remodeling is normal physiological processes of bone that is governed by two counter-processes, bone formation and resorption [2–5]. Currently, available therapies developed for osteoporosis are based on a strategy, which compounds either reduce the rate of resorption or promote bone formation, including bisphosphonates, calcitonin, estrogens, and hormone replacement therapy (HRT). Although these medications are still in use clinically for prevention or treatment of osteoporosis, they often have unwanted side effects. Although HRT remains good treatments for preventing osteoporosis still, these drugs can stimulate endometrial hyperplasia and increase the risk of endometrial carcinoma or breast cancer [6, 7]. Therefore, it is urgent to develop an alternative strategy for prevention and treatment of osteoporosis.
Herb medicines have been long used for treatment of osteoporosis in China. According to the theory of the traditional Chinese medicine, kidneys are organs that can usually strengthen the foundation of the essence, regulate development of bones, and stimulate growth of bone marrow. Well-functioned kidneys promote growth of bone marrow, resulting in strength of bones. In contrast, weakly-functioned kidneys often cause development of bone poorly, resulting in an osteoporosis-like symptom, such as lumbar and back pain, leading to an increased risk of bone fragility fractures. Therefore, osteoporosis in China has been treated by using herb supplementation, which it is believed to restore kidneys’ function effectively (Chinese reference may not be provided here).
Use of herb medicines for treatment of osteoporosis has been well documented for long history in China. However, the anti-osteoporotic mechanisms are still unknown. Our previous studies suggest that Chinese herbs increased bone formation by stimulating OPG expression and downregulating RANKL in bone marrow cells . The anti-osteoporotic effects are selective for these herbs. For example, among herb medicines studied in the previous study, only Radix Dipsaci and Pyrola Herb had significant anti-osteoporotic effects . To develop the most effective herb medicine as an alternative treatment for osteoporosis, in this study we selected additional four herbs, Semen Astragali Complanati, Rhizoma Cibotii, Herba Cistanches, and Semen Allii Tuberosi, from 24 Chinese herbs available in Chinese clinics. The criteria for selection of these herb medicines are based on: 1) those potentially effective for therapy of osteoporosis by ancient Chinese medical documents (Chinese reference, not listed here); and 2) those shown mostly effective for therapy of osteoporosis in our previous cell culture and in vivo studies (Chinese reference, not listed here).
The OPG/RANKL/RANK signaling pathway has been extensively studied as a molecular model for evaluation of drug efficacy and for understanding molecular mechanism of anti-osteoporosis in animals and humans [9–12]. The mechanism underlying the anti-osteoporotic effects of herb medicines is largely unknown. In this study, we investigated how Chinese herb medicines, especially those “kidney-supplements”, such as Semen Astragali Complanati, Rhizoma Cibotii decoction, Herba Cistanches, and Semen Allii Tuberosi, affected bone development, which was examined by measuring the activity of OPG/RANKL/RANK signaling in rats that had osteoporosis-like symptom induced by OVX.
Identification and preparation of extracts
Semen Astragali Complanati (SAC) was the dried mature seed of Astragalus complanatus R.Br. produced in China, and collected by Tianjian Medcial Co. Ltd. Wanfang Branch (Shanxi, China) in March 2007, and identified and authenticated by an expert herbalist at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences (CACMS).
Rhizoma Cibotii (RC) was the dried root stalk of Cibotium barometz (L.) J. Sm. produced in China, and collected by Zhonghong Herbal Drug Co. Ltd. (Sichuan, China) in March 2007, identified and authenticated by an expert herbalist at the Institute of Chinese Materia Medica, CACMS.
Herba Cistanches (HC) was the dried fleshy stem of Cistanche deserticola Y. C. produced in China, and collected by Taizhou Herbal Drug Co. Ltd. (Zhejiang, China) in March 2007, identified and authenticated by an expert herbalist at the Institute of Chinese Materia Medica, CACMS.
Semen Allii Tuberosi (SAT)was the dried mature seed of Allium tuberosum Rottl produced in China, and collected by Huarui Medcial Co. Ltd. (Hubei, China) in March 2007, identified and authenticated by an expert herbalist at the Institute of Chinese Materia Medica, CACMS.
All the dried herbs after collection were stored in a dry and sealed container at 4°C to prevent herbs from moisture and moth. SACD, RCD, HCD, and SATD were extracted from the herbs by boiling 300 gram of the dried SAC, RC, HC, and SAT in a 6-litre water at 100°C for 2 h. Each decoction was then concentrated to a final concentration of 1 crude drug gram per milliliter.
The voucher specimens of the plant materials used in this study were deposited in the herbarium of Institute of Chinese Materia Madica China Academy of Chinese Medical Sciences. The deposition number is 37B for Semen Astragali Complanati, 13A for Rhizoma Cibotii, 10A for Herba Cistanches, and 40A for Semen Allii Tuberosi.
Animals and experimental procedures
Ninety-four virgin Wistar female rats (weight 250 ± 20.0 g) were obtained from the Experimental Animal Center of the Academy of Military Medical Sciences (Beijing, China), and were housed in cages in the experimental animal facility at the Institute of Basic Theory of TCM, CACMS. The rats were maintained at 22°C with a 12 h light/dark cycle. During the experiment, the rats were maintained on standard rodent chow (Animal Center of the Fourth Military Medical University, Xi’an, China) that contained 0.9% calcium and 0.7% phosphate; distilled water was available ad libitum.
The rats were divided into three groups, including anormal control (NC) group (n = 12), sham control group (n = 12), and a bilaterally ovariectomized (OVX, n = 70) group using the dorsal approach7. OVX rats were randomly divided into six groups, including OVX group (n = 12), DES group (n = 12), SACD group (n = 12), RCD group (n = 12), HCD group (n = 11), and SATD group (n = 11). Diethylstilbestrol 0.008 mg/ml dissolved in distilled water was administered intragastrically to the rats in the DES group. The rats of the SACD, RCD, HCD, and SATD groups were treated with SACD 5.6 ml/ (kg body weight day), RCD 5.6 ml/ (kg body weight day), HCD 5.6 ml/ (kg body weight day), and SATD 5.6 ml/ (kg body weight day), respectively. At the same time, the rats of the NC, sham control, and OVX groups were administered with the same volume of distilled water. The treatment started four weeks after the surgery and continued for 12 weeks.
On the fifteenth and the third days before sacrifice, all the rats received tetracyclin 30 mg/kg by intraperitoneal injection. After sacrifice, proximal right tibiae were fixed in 4% paraformaldehyde for 24 h and dehydrated through an ethanol gradient of 80%, 90%, and 100% ethanol, with two days for each step. Dehydrated samples were defatted in xylene for two days before being embedded in a plastic polymer solution I (Methyl Methacrylate Monomer 100 ml + Butyl Methacrylate 35 ml + Methyl Benzoate 5 ml + Polyglycol 1.2 ml), solution II (solution I + Drying Benzoyl Peroxide 0.4 g) and solution III (solution II + Drying Benzoyl Peroxide 0.8 g) with three days for each step. Each undecalcified sample was sliced into two 5 μm longitudinal sections with microtome (Reichert-Jung 2040, Ger). One section was stained with toluidine blue and the other was used for fluorescence morphology observation. Proximal left tibiae were fixed in 4% paraformaldehyde for 24 h and decalcified in a solution of 10% EDTA (PH7.36) at 4°C for three weeks. After that, decalcified samples were dehydrated in 15% sucrose solution for 10 h. Each sample was sliced into 5 μm sections by freezing microtome (OM2563, TBS, CA). Frozen sections were fixed in acetone and were prepared for immunohistochemistry and in situ hybridization. All animals were treated according to the Guide for the Care and Use of Laboratory Animals and with the approval of the Institutional Ethics Committee of CACMS on animal experiments.
Frozen sections were mounted on glass slides and used for immunohistochemical analysis. Primary antibodies [anti-rat OPG (1:1000) and anti-rat RANKL (1:1000)] were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The tissue slides were rinsed in PBS and immersed in 0.3% hydrogen peroxide for 5 min, then, incubated with the primary antibodies for 1h at 37°C, and then rinsed with PBS three times for 3 min. The slides were then incubated with the appropriated unbiotinylated secondary antibody (Zhongshan Goldenbridge Biotechnology Co. Ltd., China) for 30 min at 37°C, followed by incubation with a solution containing DAB (Zhongshan Goldenbridge Biotechnology Co. Ltd., China) for 30 s, then rinsed in running water. After that, the slides were counterstained with Harris hematoxylin and sealed for microscopic analysis. Non-immune goat serum instead of the primary antibody was served as negative control.
All measurements were performed with the QWin image analysis system (Leica Corp., Germany). Five random images within tibiae from two sections were taken, and further analyzed by using zoomed-in field at 400× magnification. We measured the positive stained and total area under each examined field for each section. The positive stain of osteoblasts was calculated by using the percentage of stained osteoblasts over the total trabecula area under each field. The positive stain of bMSC was calculated by using the percentage of stained bMSC over a marrow cavity area excluding trabecula.
In situ hybridization
The primer sequence used in the experiments (BORSTER, China)
Primer sequence (5′-3)′
(1)5′ -TGGAC AACCC AGGAA ACCTT TCCTC CAAAA-3′,
(2)5′ -TTTGC CTGGG ACCAA AGTGA ATGCA GAGAG-3′,
(3)5′ -AGAAA TGATA GGGAA TCAGG TTCAA TCAGT-3′.
(1)5′-GCCAG CCGAG ACTAC GGCAA GTACC TGCGC-3′,
(2)5′-GGCCA GGTGG TCTGC AGCAT CGCTC TGTTC-3′,
(3)5′-TTTAT AGAAT CCTGA GACTC CATGA AAACG-3′.
All values were expressed as means ± standard deviations. All analyses were carried out using the SAS 9.1.3 (Cary, NC, USA). The difference between the groups was analyzed using the ANOVA test followed by the Tukey test.
Effects of SACD, RCD, HCD, and SATD on tibia
Effects of SACD, RCD, HCD, and SATD on the percentage of trabecular bone volume (TBV%), the percentage of trabecular bone resorption surface (TRS%), the percentage of trabecular bone formation surface (TFS%), 14Hbone mineral apposition rate (MAR), the membrane bone mineral apposition rate (mAR), and the osteoid average width (OSW) of tibia from rats
28.08 ± 7.26
3.56 ± 1.47
8.23 ± 2.69
1.30 ± 0.18
2.40 ± 0.54
5.65 ± 1.34
27.18 ± 8.78
3.40 ± 1.54
7.40 ± 2.41
1.38 ± 0.16
2.28 ± 0.47
6.20 ± 1.29
8.945 ± 3.04b
9.31 ± 2.22b
14.54 ± 3.31b
1.86 ± 0.23b
3.03 ± 0.60b
7.77 ± 1.64a
23.61 ± 4.71d
3.28 ± 1.31d
7.72 ± 2.66d
1.32 ± 0.22d
2.15 ± 0.70d
6.37 ± 1.42c
21.15 ± 4.97d
4.71 ± 1.57d
9.70 ± 2.29a, d
1.55 ± 0.26d
2.61 ± 0.31c
6.88 ± 1.56
12.10 ± 4.15b, c
7.11 ± 1.58b, c
14.93 ± 3.50b
1.92 ± 0.32b
3.09 ± 0.66b
7.13 ± 1.82
8.86 ± 2.64b
10.31 ± 2.61b
12.47 ± 3.92b
1.78 ± 0.17b
3.05 ± 0.76b
7.53 ± 1.86
10.84 ± 3.28b
10.06 ± 2.37b
12.41 ± 2.91b
1.82 ± 0.29b
2.96 ± 0.56b
6.28 ± 1.82
Although TRS%, TFS%, MAR, and mAR of tibia from sham rats were similar to those from normal rats, these indexes were significantly enhanced by OVX compared to sham or normal rats. However, the OVX effects on TRS%, TFS%, MAR, and mAR of the tibia were significantly alleviated, but not abolished, in rats treated with SACD or DES, but not RCD, HCD, or SATD (Table 2). Similarly, OSW of tibia was not significantly different between sham and normal rats, but was sharply increased by OVX. The OVX effect on OSW of the tibia from rats was not changed by treatment with any of herbs (Table 2).
Effects of SACD, RCD, HCD, and SATD on protein expression of OPG and RANKL in OB and bMSC
Effects of SACD, RCD, HCD, and SATD on the protein expression of OPG and RANKL in OB and bMSC from tibia of rats
The protein expression of OPG in OB
The protein expression of OPG in bMSC
The protein expression of RANKL in OB
The protein expression of RANKL in bMSC
1.66 ± 0.42
7.18 ± 1.72
1.08 ± 0.27
4.77 ± 1.82
1.72 ± 0.52
6.48 ± 1.81
1.17 ± 0.28
4.55 ± 1.75
0.76 ± 0.23b
3.06 ± 1.28b
1.82 ± 0.41b
9.06 ± 2.11b
1.62 ± 0.38d, c
6.24 ± 1.91d, c
1.23 ± 0.34d, c
5.34 ± 1.54d, c
1.51 ± 0.45d, c
5.70 ± 1.63d, c
1.30 ± 0.30d, c
6.40 ± 1.88a, d, c
1.25 ± 0.41a, d
4.63 ± 1.23b, d
1.77 ± 0.36b
8.04 ± 2.01b
0.72 ± 0.24b
3.10 ± 1.05b
1.87 ± 0.36b
9.14 ± 2.03b
0.94 ± 0.30b
3.60 ± 1.12b
1.75 ± 0.35b
8.74 ± 1.84b
As expected, protein expression of the bone resorption marker RANKL in OB and bMSC from rats in the sham group was similar to that in normal control group. OVX, however, remarkably induced RANKL expression in OB and bMSC from rat tibias (Figure 2B). The OVX effects on RANKL expression in OB and bMSC were significantly reversed in rats treated with either SACD or DES, but not with RCD, HCD, or SATD. The results in Figure 2B were confirmed by quantitative results of RANKL in tibia (Table 3).
The ratio of RANKL/OPG has been used as an index for evaluation of activity of bone remodeling . To help visualize the effects of these Chinese herb supplements on bone remodeling, we re-plotted the data from Figure 2A/B in Figure 2C, of which the expression pattern is similar to that in Figure 2A/B.
Effects of SACD, RCD, HCD, and SATD on OPG and RANKL mRNA expression in OB and bMSC from tibia of ovariectomized rats
Effect of SACD, RCD, HCD, and SATD on OPG and RANKL mRNA expression in * OB and bMSC from rats’ tibia
OPG mRNA expression in OB*
OPG mRNA expression in bMSC*
RANKL mRNA expression in OB
RANKL mRNA expression in bMSC
2.07 ± 0.46
7.33 ± 1.82
1.47 ± 0.52
5.84 ± 1.69
2.15 ± 0.66
7.65 ± 2.19
1.60 ± 0.50
6.07 ± 1.79
1.05 ± 0.40b
3.30 ± 1.03b
2.41 ± 0.53b
9.94 ± 2.16b
1.98 ± 0.40d
6.92 ± 1.65d
1.70 ± 0.48d
6.26 ± 1.67d
1.82 ± 0.36d
6.44 ± 1.69d
1.83 ± 0.44d
6.87 ± 1.71d
1.43 ± 0.43b, c
5.00 ± 1.46b, d
2.18 ± 0.52a
8.87 ± 1.91b
0.97 ± 0.36b
3.28 ± 1.20b
2.20 ± 0.60a
9.82 ± 1.95b
1.28 ± 0.38b
3.69 ± 1.47b
2.10 ± 0.48a
9.51 ± 1.86b
As expected, RANKL mRNA expression in OB and bMSC from tibia of rats in the sham group remains low and similar to that in the normal control group, but was reduced significantly by OVX treatment (Figure 3B). However, OVX-caused effects on RANKL mRNA expression were remarkably alleviated, although not recovered to the level in normal control, in rats treated with either DES or SACD, but not with RCD, HCD, or SATD (Figure 3B). Results in Figures 3A/B were verified by quantitative measurements of RANKL mRNA in OB and bMSC from tibia of rats (Table 4).
Although Chinese mherbs have shown an effective therapeutic strategy for Chinese people. the exact mechanism underlying is still unknown. Our previous study and others showed that Radix Dipsaci decoction and Pyrola Herb decoction enhanced significantly bone formation in OVX rats [8, 14]. Our results in this study showed that Chinese herbs SACD and RCD increased bone formation by stimulating OPG expression and downregulating RANKL expression in OB and bMSC.
Resistance to bone fracture depends on its structure and mechanic properties, which are maintained by lifelong bone remodeling . Bone remodeling is controlled dynamically by two-counter balanced processes, bone resorption and bone formation [2, 3]. Interruption of the counter-balanced processes leads to an abnormal bone remodeling, resulting further in deterioration of overall skeleton structure. Osteoporosis is highly regulated by many factors including genetic background, age, and sex hormone. The risk of osteoporosis in postmenopausal women is developed incrweasingly due to estrogen deficiency, which causes overexpression of pro-inflammatory cytokines provoking activity of bone resorption . Discovery of OPG, RANKL, and RANK has shed light on understanding of regulation of bone modeling and remodeling . OPG is one of the tumor necrosis factor receptor (TNFR) superfamily members , and a soluble glycoprotein secreted by various mesenchymal-derived cells, such as osteoblasts  and bone marrow stromal cells . OPG acts as a soluble decoy receptor for RANKL and, thus, decreases bone resorption. RANKL is a TNF-related cytokine expressed by various bone cells, including osteoblasts and their immature precursors , activated T lymphocytes and B lymphocytes . RANKL is essential for mediating bone resorption, which stimulates osteoclastogenesis and osteoclast activity by binding to the osteoclast surface receptor [20, 21]. RANK is also a member of the TNFR family  and is highly expressed by a wide variety of cells, such as osteoclast precursors, mature osteoclasts, B and T lymphocytes, dendritic cells, fibroblasts, and articular chondrocytes, and is considered as a natural receptor of RANKL . The binding of RANKL to RANK leads to the activation of signaling pathways, which regulates function of osteoclast. OPG protects bone from excessive resorption by inhibition of RANKLbinding to RANK . Thus, the OPG/RANKL/RANK signaling pathway is considered as a key cytokine system for controlling bone modeling and remodeling. In this study, we examined the herbal medicines’ effects on bone morphometric indexes and OPG/RANKL expression in OB and bMSC from OVX rat tibia, and found that only SACD, similar to DES treatment, can alleviate the loss of tibia bone mass that was induced by OVX treatment.
Previous studies demonstrated that overexpression of OPG gene in mice resulted in high bone mass and a remarkable reduction in osteoclast number and its activity, while low BMD, increased numbers of osteoclasts and more woven bone were observed in OPG knockout (KO) mice . Injection of recombinant RANKL and OPG to mice caused a rapid and significant increase in bone turnover signals (BTSs) and number of osteoclasts . One OPG injection resulted in a decreased BTS within two hours, and a 50% to 60% reduction in osteoclast numbers within 12 to 24 hours . Our experiments showed that expression of OPG in OB and bMSC from OVX rats treated with either SACD or RCD was significantly higher than that from control, while RANKL expression was much lower than that from control, suggesting that SACD and RCD treatment induced expression of OPG, but decreased RANKL expression, in OB and bMSC.
Intriguingly, we observed that the medicines tested in this study showed similar effects to DES, suggesting that, to some extent, these medicines may contain certain amount of active components, such as phytoestrogen, although the exact active components in these medicines have not been isolated yet. Further functional characterization of these active components from these medicines, especially SACD, may be needed and helpful for understanding the mechanism underlying the medicine-induced effect.
Data from this study suggest that SACD enhanced bone formation and decreased bone resorption significantly in the treated OVX rats. The mechanism underlying SACD-induced effects in OVX rats may be explained by overexpression of bone formation marker OPG and suppression of bone resorption marker RANKL in OB and bMSC from rats’ tibia.
Semen Astragali Complanati
Semen Allii Tuberosi
Semen Astragali Complanati decoction
Rhizoma Cibotii decoction
Herba Cistanches decoction
Semen Allii Tuberosi decoction
Bone marrow stromal cells
Mineralization rate of trabeculae
Mineralization rate of bone cortex
Osteoid mean width
Trabecular bone volume
Trabecular formation surface
Trabecular resorption surface
This project is financially supported by specialized scientific research institutes of social welfare, the Ministry of Science and Technology, China (No. 2005DIB1J168).
- Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993, 94: 646-650.
- Chavassieux P, Seeman E, Delmas PD: Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev. 2007, 28: 151-164.View ArticlePubMedGoogle Scholar
- Martin TJ, Sims NA: Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005, 11: 76-81. 10.1016/j.molmed.2004.12.004.View ArticlePubMedGoogle Scholar
- Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J: Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol. 2005, 166: 467-476. 10.1016/S0002-9440(10)62269-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K: Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res. 2007, 22: 487-494. 10.1359/jbmr.070109.View ArticlePubMedGoogle Scholar
- Acconcia F, Barnes CJ, Kumar R: Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology. 2006, 147: 1203-1212.View ArticlePubMedGoogle Scholar
- The Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal Woman. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.View ArticleGoogle Scholar
- Liu M, Xiao GG, Rong P, Zhang Z, Dong J, Zhao H, Li H, Li Y, Pan J, Liu H, Wang W, Zha Q, Ju D: Long-term therapeutic effects of Radix Dipsaci, Pyrola Herb, and Cynomorium Songaricum on bone metabolism of ovariectomized rats. BMC Complement Altern Med. 2012, AcceptedGoogle Scholar
- Yasujima M, Abe K, Kanazawa M, Yoshida K, Kohzuki M, Sato M, Takeuchi K, Omata K, Tsunoda K, Kudo K: Effects of antihypertensive drugs on renal function and atrial natriuretic polypeptide in spontaneously hypertensive rats with renal ablation. Tohoku J Exp Med. 1989, 158: 85-94. 10.1620/tjem.158.85.View ArticlePubMedGoogle Scholar
- Dunlap JE: Preventing broken appointments. Dent Econ. 1976, 66: 44-5. 47Google Scholar
- Tyrovola JB, Spyropoulos MN, Makou M, Perrea D: Root resorption and the OPG/RANKL/RANK system: a mini review. J Oral Sci. 2008, 50: 367-376. 10.2334/josnusd.50.367.View ArticlePubMedGoogle Scholar
- Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004, 292: 490-495. 10.1001/jama.292.4.490.View ArticlePubMedGoogle Scholar
- Van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewe RB, Dijkmans BA, Lems WF: Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 1623-1628. 10.1136/ard.2009.121764.View ArticlePubMedGoogle Scholar
- Liu ZG, Zhang R, Li C, Ma X, Liu L, Wang JP, Mei QB: The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats. J Ethnopharmacol. 2009, 123: 74-81. 10.1016/j.jep.2009.02.025.View ArticlePubMedGoogle Scholar
- Seeman E, Delmas PD: Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006, 354: 2250-2261. 10.1056/NEJMra053077.View ArticlePubMedGoogle Scholar
- Kearns AE, Khosla S, Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008, 29: 155-192.View ArticlePubMedGoogle Scholar
- Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, Truneh A: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 1997, 204: 35-46. 10.1016/S0378-1119(97)00509-X.View ArticlePubMedGoogle Scholar
- Woo KM, Choi Y, Ko SH, Ko JS, Oh KO, Kim KK: Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. Exp Mol Med. 2002, 34: 347-352. 10.1038/emm.2002.49.View ArticlePubMedGoogle Scholar
- Kondo T, Kitazawa R, Maeda S, Kitazawa S: 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res. 2004, 19: 1411-1419. 10.1359/JBMR.040604.View ArticlePubMedGoogle Scholar
- Kwan TS, Padrines M, Theoleyre S, Heymann D, Fortun Y: IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004, 15: 49-60. 10.1016/j.cytogfr.2003.10.005.View ArticleGoogle Scholar
- Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001, 142: 5050-5055. 10.1210/en.142.12.5050.View ArticlePubMedGoogle Scholar
- Hofbauer LC, Heufelder AE: Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases. Dtsch Med Wochenschr. 2001, 126: 145-150. 10.1055/s-2001-11050.View ArticlePubMedGoogle Scholar
- Gravallese EM, Goldring SR: Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 2000, 43: 2143-2151. 10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12: 1260-1268. 10.1101/gad.12.9.1260.View ArticlePubMedPubMed CentralGoogle Scholar
- Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999, 145: 527-538. 10.1083/jcb.145.3.527.View ArticlePubMedPubMed CentralGoogle Scholar
- Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N: Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone. 1998, 23: 495-498. 10.1016/S8756-3282(98)00141-0.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/141/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.